Interferon-α: A new target for therapy in systemic lupus erythematosus?

Arthritis and Rheumatism

Volumn 48, Issue 9, 2003, Pages 2396-2401

  Crow, Mary K ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERFERON;

AUTOIMMUNITY; DRUG TARGETING; EDITORIAL; HUMAN; IMMUNE SYSTEM; LUPUS ERYTHEMATOSUS; PATHOGENESIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

HUMANS; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 0141676493     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11226     Document Type: Editorial

References (42)

1. Blomberg S, Eloranta M-L, Magnusson M, Alm GV, Rönnblom L. Expression of the markers BDCA-2 and BDCA-4 and production of interferon-α by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum 2003;48:2524-32.
2. Issacs A. Interferon. Adv Virus Res 1963;10:1-38.
3. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979;301:5-8.
4. Martal JL, Chene NM, Huynh LP, L'Haridon RM, Reinaud PB, Guillomot MW, et al. IFN-tau: A novel subtype I IFN1. Structural characteristics, non-ubiquitous expression, structure-function relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities. Biochimie 1998;80:755-77.
5. Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982;216:429-31.
6. Yee AMF, Yip YK, Fischer HD, Buyon JP. Serum activity that confers acid lability to α-interferon in systemic lupus erythematosus: its association with disease activity and its independence from circulating α-interferon. Arthritis Rheum 1990;33:563-8.
7. Rich SA. Human lupus inclusions and interferon. Science 1981;213:772-5.
8. Rönnblom LE, Alm GV, Öberg KE. Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990;227:207-10.
9. Svensson H, Johannisson A, Nikkila T, Alm GV, Cederblad B. The cell surface phenotype of human natural interferon-α producing cells as determined by flow cytometry. Scand J Immunol 1996;44:164-72.
10. Vallin H, Blomberg S, Alm GV, Cederblad B, Rönnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-α) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 1999;115:196-202.
11. Vallin H, Perers A, Alm GV, Rönnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus. J Immunol 1999;163:6306-13.
12. Båve U, Alm GV, Rönnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-α inducer. J Immunol 2000;165:3519-26.
13. Båve U, Vallin H, Alm GV, Rönnblom L. Activation of natural interferon-α producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines. J Autoimmun 2001;17:71-80.
14. Magnusson M, Magnusson S, Vallin H, Rönnblom L, Alm GV. Importance of CpG dinucleotides in activation of natural IFN-alpha-producing cells by a lupus-related oligodeoxynucleotide. Scand J Immunol 2001;54:543-50.
15. Batteux F, Palmer P, Daeron M, Weill B, Lebon P. FcgammaRII (CD32)-dependent induction of interferon-α by serum from patients with lupus erythematosus. Eur Cytokine Netw 1999;10:509-14.
16. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284:1835-7.
17. Rönnblom L, Alm GV. A pivotal role for the natural interferon α-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001;194:F59-63.
18. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664-71.
19. Bell DA, Morrison B, VandenBygaart P. Immunogenic DNA-related factors: nucleosomes spontaneously released from normal murine lymphoid cells stimulate proliferation and immunoglobulin synthesis of normal mouse lymphocytes. J Clin Invest 1990;85:1487-96.
20. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-7.
21. Scheinecker C, Zwölfer B, Köller M, Männer G, Smolen JS. Alterations of dendritic cells in systemic lupus erythematosus: phenotypic and functional deficiencies. Arthritis Rheum 2001;44:856-65.
22. Blomberg S, Eloranta M-L, Cederblad B, Nordlin K, Alm GV, Rönnblom L. Presence of cutaneous interferon-α producing cells in patients with systemic lupus erythematosus. Lupus 2001;10:484-90.
23. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001;159:237-43.
24. Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F, et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferonα/β induction. J Exp Med 2001;194:1823-34.
25. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 2001;294:1540-3.
26. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610-5.
27. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23.
28. Crow MK, George S, Paget SA, Ly N, Woodward R, Fry K, et al. Expression of an interferon-alpha gene program in SLE [abstract]. Arthritis Rheum 2002;46 Suppl 9:S281.
29. Preble OT, Rothko K, Klippel JH, Friedman RM, Johnston MI. Interferon-induced 2′-5′ adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon. J Exp Med 1983;157:2140-6.
30. Rozzo SJ, Allard JD, Choubey D, Vyse TJ, Izui S, Peltz G, et al. Evidence for an interferon-inducible gene, Ifi2O2, in the susceptibility to systemic lupus. Immunity 2001;15:435-43.
31. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003;197:777-88.
32. Crow MK. Studies of autologous T cell activation in the Kunkel laboratory. Lupus 2003;12:163-9.
33. Chernysheva AD, Kirou KA, Crow MK. T cell proliferation induced by autologous non-T cells is a response to apoptotic cells processed by dendritic cells. J Immunol 2002;169:1241-50.
34. Pisetsky DS, Wenk KS, Reich CF III. The role of CpG sequences in the induction of anti-DNA antibodies. Clin Immunol 2001;100:157-63.
35. Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998;161:1947-53.
36. Paquette RL, Hsu NC, Kiertscher SM, Park AN, Tran L, Roth MD, et al. Interferon-α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol 1998;64:358-67.
37. Aman MJ, Tretter T, Eisenbeis I, Bug G, Decker T, Aulitzky WE, et al. Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes. Blood 1996;87:4731-6.
38. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli G, Tough D. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001;14:461-70.
39. Kirou KA, Vakkalanka RK, Butler MJ, Crow MK. Induction of Fas ligand-mediated apoptosis by interferon-α. Clin Immunol 2000;95:218-26.
40. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994;152:3685-92.
41. Georgescu L, Vakkalanka RK, Elkon KB, Crow MK. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest 1997;100:2622-33.
42. Chuntharapai A, Lai J, Huang X, Gibbs V, Kim KJ, Presta LG, et al. Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE. Cytokine 2001;15:250-60.